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The ‘worried-well’, insulin
resistance and metformin
therapy
To the Editor: I would like to respond to the letter with the
above title that appeared in a recent issue of the Journal.1 The
authors wrote: ‘The decision whether to use insulin sensitisers
in patients with impaired glucose tolerance is still being
debated, but there is certainly no evidence that these drugs will
either help the patient lose weight or prevent progression to
diabetes in individuals without dysglycaemia.’   
Metformin has been tried in obese individuals without
diabetes as a tool for inducing weight loss.  Several studies2-5
found that metformin decreased body mass index (BMI), waist-
to-hip ratio and total cholesterol and increased high-density
lipoprotein cholesterol in obese but non-diabetic patients.
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Zebras and bergkwaggas – the
case for research on rare and very
rare genetic diseases in South
Africa
To the Editor: I recently had the privilege of learning firsthand
about some very uncommon genetic diseases during a clinical
infectious diseases rotation at the National Institutes of Health
(NIH) in Bethesda, Maryland. Most of our patients had rare
inherited immunodeficiency syndromes, such as chronic
granulomatous disease and Job’s syndrome, resulting in
chronic intractable infections with unusual mycobacteria and
fungi. These patients came from around the USA, sometimes
even from other countries, for periodic elective admissions to
the hospital section for a full workup. One of our patients had
befriended a patient from another clinical section, and they
shared a ride from Virginia when they came for their annual
admissions. When I discreetly enquired what ‘zebra’ (the US
medical student term for a very rare disease) the friend might
have, the nurse replied: ‘Oh that must be the guy from Tangier
Island with Tangier disease.’ 
It turns out that Tangier disease (TD), an extremely rare (less
than 50 cases reported worldwide) genetic disorder of
